vs
Enovis CORP（ENOV）与捷迈邦美（ZBH）财务数据对比。点击上方公司名可切换其他公司
捷迈邦美的季度营收约是Enovis CORP的4.1倍（$2.2B vs $548.9M）。捷迈邦美净利率更高（6.2% vs -104.1%，领先110.3%）。捷迈邦美同比增速更快（10.9% vs -2.2%）。捷迈邦美自由现金流更多（$442.6M vs $29.1M）。过去两年Enovis CORP的营收复合增速更高（9.8% vs 9.0%）
Enovis是一家专注于骨科领域的医疗科技企业，其前身是1995年由米切尔·雷尔斯和史蒂文·雷尔斯兄弟创立的科尔法克斯公司。公司总部位于特拉华州威尔明顿，目前在全球12个地点开展业务，拥有超过5000名员工，于纽约证券交易所上市，股票代码为ENOV。
捷迈邦美是一家美国上市的医疗设备企业，1927年成立，最初以生产铝制夹板为核心业务，总部设于印第安纳州华沙市，是当地医疗设备产业集群的核心成员，在全球骨科医疗器械领域拥有较高知名度。
ENOV vs ZBH — 直观对比
营收规模更大
ZBH
是对方的4.1倍
$548.9M
营收增速更快
ZBH
高出13.0%
-2.2%
净利率更高
ZBH
高出110.3%
-104.1%
自由现金流更多
ZBH
多$413.5M
$29.1M
两年增速更快
ENOV
近两年复合增速
9.0%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $548.9M | $2.2B |
| 净利润 | $-571.1M | $139.4M |
| 毛利率 | 59.9% | 64.7% |
| 营业利润率 | -101.7% | 6.9% |
| 净利率 | -104.1% | 6.2% |
| 营收同比 | -2.2% | 10.9% |
| 净利润同比 | 18.8% | -41.8% |
| 每股收益（稀释后） | $-9.99 | $0.71 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ENOVZBH
| Q4 25 | $548.9M | $2.2B | ||
| Q3 25 | $564.5M | $2.0B | ||
| Q2 25 | $558.8M | $2.1B | ||
| Q1 25 | — | $1.9B | ||
| Q4 24 | $561.0M | $2.0B | ||
| Q3 24 | $505.2M | $1.8B | ||
| Q2 24 | $525.2M | $1.9B | ||
| Q1 24 | $516.3M | $1.9B |
净利润ENOVZBH
| Q4 25 | $-571.1M | $139.4M | ||
| Q3 25 | $-36.7M | $230.9M | ||
| Q2 25 | $-56.0M | $152.8M | ||
| Q1 25 | — | $182.0M | ||
| Q4 24 | $-703.2M | $239.5M | ||
| Q3 24 | $-31.5M | $249.1M | ||
| Q2 24 | $-18.6M | $242.8M | ||
| Q1 24 | $-72.0M | $172.4M |
毛利率ENOVZBH
| Q4 25 | 59.9% | 64.7% | ||
| Q3 25 | 59.3% | 72.1% | ||
| Q2 25 | 59.5% | 71.5% | ||
| Q1 25 | — | 71.2% | ||
| Q4 24 | 54.8% | 71.0% | ||
| Q3 24 | 56.7% | 70.5% | ||
| Q2 24 | 55.0% | 71.5% | ||
| Q1 24 | 57.7% | 72.9% |
营业利润率ENOVZBH
| Q4 25 | -101.7% | 6.9% | ||
| Q3 25 | -3.0% | 17.6% | ||
| Q2 25 | -8.4% | 14.4% | ||
| Q1 25 | — | 15.3% | ||
| Q4 24 | -118.5% | 19.2% | ||
| Q3 24 | -6.3% | 15.3% | ||
| Q2 24 | -8.4% | 18.1% | ||
| Q1 24 | -6.8% | 14.1% |
净利率ENOVZBH
| Q4 25 | -104.1% | 6.2% | ||
| Q3 25 | -6.5% | 11.5% | ||
| Q2 25 | -10.0% | 7.4% | ||
| Q1 25 | — | 9.5% | ||
| Q4 24 | -125.4% | 11.8% | ||
| Q3 24 | -6.2% | 13.7% | ||
| Q2 24 | -3.5% | 12.5% | ||
| Q1 24 | -13.9% | 9.1% |
每股收益（稀释后）ENOVZBH
| Q4 25 | $-9.99 | $0.71 | ||
| Q3 25 | $-0.64 | $1.16 | ||
| Q2 25 | $-0.98 | $0.77 | ||
| Q1 25 | — | $0.91 | ||
| Q4 24 | $-12.69 | $1.18 | ||
| Q3 24 | $-0.58 | $1.23 | ||
| Q2 24 | $-0.34 | $1.18 | ||
| Q1 24 | $-1.32 | $0.84 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $33.6M | $591.9M |
| 总债务越低越好 | $1.4B | — |
| 股东权益账面价值 | $2.0B | $12.7B |
| 总资产 | $4.4B | $23.1B |
| 负债/权益比越低杠杆越低 | 0.67× | — |
8季度趋势，按日历期对齐
现金及短期投资ENOVZBH
| Q4 25 | $33.6M | $591.9M | ||
| Q3 25 | $44.1M | $1.3B | ||
| Q2 25 | $38.5M | $556.9M | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | $48.2M | $525.5M | ||
| Q3 24 | $35.4M | $569.0M | ||
| Q2 24 | $35.0M | $420.1M | ||
| Q1 24 | $66.3M | $393.0M |
总债务ENOVZBH
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | $1.4B | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $1.3B | — | ||
| Q2 24 | $1.3B | — | ||
| Q1 24 | $1.3B | — |
股东权益ENOVZBH
| Q4 25 | $2.0B | $12.7B | ||
| Q3 25 | $2.6B | $12.8B | ||
| Q2 25 | $2.6B | $12.5B | ||
| Q1 25 | — | $12.4B | ||
| Q4 24 | $2.6B | $12.5B | ||
| Q3 24 | $3.3B | $12.4B | ||
| Q2 24 | $3.3B | $12.7B | ||
| Q1 24 | $3.3B | $12.6B |
总资产ENOVZBH
| Q4 25 | $4.4B | $23.1B | ||
| Q3 25 | $5.0B | $23.5B | ||
| Q2 25 | $4.9B | $22.9B | ||
| Q1 25 | — | $22.2B | ||
| Q4 24 | $4.7B | $21.4B | ||
| Q3 24 | $5.6B | $21.7B | ||
| Q2 24 | $5.4B | $21.5B | ||
| Q1 24 | $5.5B | $21.5B |
负债/权益比ENOVZBH
| Q4 25 | 0.67× | — | ||
| Q3 25 | 0.54× | — | ||
| Q2 25 | 0.53× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.52× | — | ||
| Q3 24 | 0.40× | — | ||
| Q2 24 | 0.41× | — | ||
| Q1 24 | 0.40× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $82.6M | $517.4M |
| 自由现金流经营现金流 - 资本支出 | $29.1M | $442.6M |
| 自由现金流率自由现金流/营收 | 5.3% | 19.7% |
| 资本支出强度资本支出/营收 | 9.7% | 3.3% |
| 现金转化率经营现金流/净利润 | — | 3.71× |
| 过去12个月自由现金流最近4个季度 | $22.8M | $1.5B |
8季度趋势，按日历期对齐
经营现金流ENOVZBH
| Q4 25 | $82.6M | $517.4M | ||
| Q3 25 | $47.8M | $418.7M | ||
| Q2 25 | $-1.6M | $378.2M | ||
| Q1 25 | — | $382.8M | ||
| Q4 24 | $88.3M | $506.3M | ||
| Q3 24 | $53.6M | $395.7M | ||
| Q2 24 | $7.8M | $369.4M | ||
| Q1 24 | $-36.2M | $228.0M |
自由现金流ENOVZBH
| Q4 25 | $29.1M | $442.6M | ||
| Q3 25 | $3.4M | $363.7M | ||
| Q2 25 | $-44.9M | $328.1M | ||
| Q1 25 | — | $338.2M | ||
| Q4 24 | $35.1M | $454.8M | ||
| Q3 24 | $2.4M | $351.2M | ||
| Q2 24 | $-31.6M | $316.7M | ||
| Q1 24 | $-73.1M | $172.9M |
自由现金流率ENOVZBH
| Q4 25 | 5.3% | 19.7% | ||
| Q3 25 | 0.6% | 18.2% | ||
| Q2 25 | -8.0% | 15.8% | ||
| Q1 25 | — | 17.7% | ||
| Q4 24 | 6.3% | 22.5% | ||
| Q3 24 | 0.5% | 19.3% | ||
| Q2 24 | -6.0% | 16.3% | ||
| Q1 24 | -14.2% | 9.2% |
资本支出强度ENOVZBH
| Q4 25 | 9.7% | 3.3% | ||
| Q3 25 | 7.9% | 2.7% | ||
| Q2 25 | 7.7% | 2.4% | ||
| Q1 25 | — | 2.3% | ||
| Q4 24 | 9.5% | 2.5% | ||
| Q3 24 | 10.1% | 2.4% | ||
| Q2 24 | 7.5% | 2.7% | ||
| Q1 24 | 7.2% | 2.9% |
现金转化率ENOVZBH
| Q4 25 | — | 3.71× | ||
| Q3 25 | — | 1.81× | ||
| Q2 25 | — | 2.48× | ||
| Q1 25 | — | 2.10× | ||
| Q4 24 | — | 2.11× | ||
| Q3 24 | — | 1.59× | ||
| Q2 24 | — | 1.52× | ||
| Q1 24 | — | 1.32× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ENOV
| Reconstructive Segment | $258.0M | 47% |
| Surgical | $129.0M | 23% |
| Prevention And Recovery | $92.6M | 17% |
| Other Prevention And Recovery | $71.4M | 13% |
ZBH
| Knees | $911.0M | 41% |
| SET | $587.6M | 26% |
| Hips | $555.4M | 25% |
| Technology And Data Bone Cement And Surgical | $189.8M | 8% |
